The article, published in The Journal of Headache and Pain, compared the efficacy of Theranica’s Nerivio™ REN device to previous acute care in the same patients. The post-hoc analysis used data from a randomized, double-blind, sham-controlled pivotal study in adult migraine patients. Usual care was the preferred treatment as identified by each individual subject in a run-in phase prior to be introduced to the REN device, and included specific acute migraine medications like triptans, non-specific acute pain relief medications (prescription or over the counter) etc., and non-pharmacological treatments.
New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications
Theranica Appoints Senior Executives to Lead its New USA Subsidiary
Theranica announces the establishment of its wholly-owned subsidiary company, Theranica USA, headquartered in Montclair, NJ, and the appointment of senior executives to lead the commercialization of Nerivio.
FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device
The U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra®, utilizing Remote Electrical Neuromodulation for the acute treatment of migraine.
OMRON VENTURES Joins Theranica’s Series B Funding Round as Strategic Investor
OMRON VENTURES has joined its $35 million series B funding round. OMRON VENTURES has committed to providing key insight and support to Theranica as the remote electrical neuromodulation startup continues to develop its unique approach to acute treatment of migraine
Theranica Raises $35M to Bring Innovative Migraine Device to the USA
We are happy to announce the closing of our round B of financing, of $35 Million, led by aMoon, Israel’s largest healthcare VC. All existing investors of the company – Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa – participated in the round.
Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine
At the annual headache symposium of the American Headache Society, Theranica, a biomedical technology company developing advanced electroceuticals for migraine and other idiopathic pain disorders, will announce the results of TCH-003, a pivotal study of the Nerivio Migra, a novel non-invasive neuromodulation device for the acute treatment of migraine.
Theranica secures its Round A of financing, raises $6M
Theranica Bio-Electronics, a bio-medical technology company developing advanced electroceuticals for migraine and other prevalent diseases, announced the closing of its round A of financing, led by Lightspeed Venture Partners. Other investors participating in the round are LionBird venture capital firm and Corundum Open Innovation.
American Academy of Neurology - Study: Wireless Stimulation May Ease Migraine Pain as Well as Drugs
These results need to be confirmed with additional studies, but they are exciting,” said study author David Yarnitsky, MD, of Technion Faculty of Medicine in Haifa, Israel, and a member of the Medical Advisory Board for Theranica, maker of the stimulation device. “People with migraine are looking for non-drug treatments, and this new device is easy to use, has no side effects and can be conveniently used in work or social settings.”
Theranica Raises Seed, Nominates Medical Advisory Board
theranica raises seed nominated mab